Developer docs
API playgroundTry for free, no card

Search company profiles

AlloSource

Full company profile

uuid00088gd

Namestring
AlloSource
Legal namestring
AlloSource
Websiteurl
allosource.org
Company typeenum
Private
Founded yearint
1994
Descriptiontext

AlloSource is a nonprofit human tissue processor founded in 1994 in Centennial, Colorado, by three Organ Procurement Organizations (Donor Alliance, Gift of Hope Organ & Tissue Donor Network, and Iowa Donor Network). It transforms donated human tissue into allograft products across 11 tissue types — dermis, cartilage, tendon, fascia, bone, and amnion — serving 8 surgical specialties including orthopedics, sports medicine, spine, plastics and reconstruction, urogynecology, burn and wound care, and foot and ankle. The company is governed by a board composed of OPO executives, with no external PE or VC ownership, and operates from a 160,000-square-foot headquarters containing 37 clean rooms and multiple laboratory spaces.

AlloSource's product platform rests on three proprietary processing technologies: ViaTrue Cryopreservation (controlled-rate freezing of fresh cartilage within 72 hours of donor death, maintaining high chondrocyte viability for up to two years), AlloTrue Tissue Cleansing (deep-tissue cleansing that removes blood and lipids while preserving biomechanical properties), and DermaTrue Decellularization (which removes cellular debris to render tissue acellular while preserving native collagen structure). Products such as AlloMend are terminally sterilized with e-beam technology to a Sterility Assurance Level of 10^-6. The company holds 100+ patents across these processes and has recorded zero confirmed disease transmission incidents over 20+ years of processing, with an estimated transmission risk below 1 in 1.6 million. Differentiated pre-sutured ready-to-use devices (AceConnex for hip labral reconstruction, ReConnex for ACL reconstruction) eliminate 24-45 minutes of OR preparation time.

AlloSource generates revenue by processing and distributing allograft products to hospitals, surgery centers, and orthopedic practices. Distribution is handled through an independent distributor network and a field-based direct sales team, supported by nine regional distribution centers across the United States and contracts with all national GPOs and hundreds of integrated delivery networks. International distribution extends to the Asia Pacific Rim, EU, Latin America, and South America under Health Canada, EU tissue directive, Korean, and Taiwan FDA compliance. Pricing is not publicly disclosed; hospital purchasing terms include annual CPI-linked price adjustment caps. The company employs more than 500 people and distributes more than 200,000 allografts annually (up from approximately 14,000 in 1994), with key leadership including President and CEO Dean Elliott, CFO Yan Deng, and Chief Commercial Officer Kevin Whitten.

Short descriptiontext

AlloSource is a nonprofit human tissue processor that transforms donated tissue into 200,000+ allograft products annually across 11 tissue types and 8 surgical specialties, serving hospitals, surgery centers, and orthopedic practices in the US and internationally through direct sales and distributors.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersCentennial, United States
HQ citystring
Centennial
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices8 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
human tissue allografts, acellular dermal matrix, orthopedic tissue products, bone grafting materials, tissue banking services
Industry1 code
PRIMARYHLAAAGAH
Cartilage, Bone & Musculoskeletal Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Surgical Appliance and Supplies Manufacturing339113
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
Product category
Human Tissue Allografts
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Human Tissue Allograft Products
TypeOne Time License
Description

AlloSource generates revenue by processing and distributing human tissue allografts (dermis, cartilage, tendon, fascia, bone, and amnion) to hospitals, surgery centers, and orthopedic surgeons for use in various surgical procedures including knee replacement, bone grafts, spinal fusions, eye surgery, and skin grafts.

allosource.org
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Operations, Personnel, Technology or R&D, Supply Chain, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 11 records shown
1AceConnex
Description

Pre-Sutured Fascia product line for hip labral reconstruction

allosource.org
+10 more records
Core offering1 text field

AlloSource processes donated human tissue into allograft products for surgical use, offering a comprehensive portfolio of dermis, cartilage, tendon, fascia, bone, and amnion allografts serving orthopedics, sports medicine, spine, plastics/reconstruction, urogynecology, burn, and wound care specialties. Products are developed using proprietary processing technologies including ViaTrue cryopreservation, AlloTrue cleansing, and DermaTrue decellularization, and are distributed to hospitals, surgery centers, and orthopedic practices.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Zero confirmed disease transmission incidents in over 20 years of tissue processing
+5 more records
Product overview1 text field

AlloSource is one of the largest human tissue providers, offering a comprehensive portfolio of innovative allograft products derived from donated human tissue. The portfolio includes multiple product lines organized by tissue type: Acellular Dermal Matrix products (AlloMend line with variants including Duo, Ultra Thick, Extra-Large, and Mesh Shaped), Skin products (AlloSkin, PureSkin), Cartilage products (ProChondrix CR, Costal Cartilage), Bone products (AlloFuse line including Select, Cervical Spacers, Fibers, Paste/Putty/Gel; Cortical/Cancellous Bone, Structural Bone, Reconstructive Bone), Tendon/Ligament products (AlloConnex portfolio including ReConnex Pre-Sutured Tendon, AceConnex Pre-Sutured Fascia), Fascia products (UroConnex), and Amnion products (AlloWrap). Products serve multiple surgical specialties including burn care, foot & ankle, orthopedics, plastics/reconstruction, spine, sports medicine, urogynecology, and wound care.

Product and service20 records
1ReConnex Pre-Sutured Tendon
CategoryTendons / Sports Medicine
Description

FDA 510(k) cleared ready-to-use sterile pre-sutured tendon allograft designed for all-inside Anterior Cruciate Ligament (ACL) reconstruction procedures. Features validated suture and knot pull-out strength with diameters 8.0-10.5mm and lengths 66mm +/-4mm.

2UroConnex
CategoryFascia / Urogynecology
Description

Fascia allograft offered in freeze-dried and frozen varieties with a wide range of sizes for structural support in surgical procedures. Provides an alternative to autologous fascia with terminal sterilization (irradiated to SAL of 10-6).

3AceConnex Pre-Sutured Fascia
CategoryFascia / Sports Medicine
Description

Only 510(k) cleared pre-sutured fascia allograft for hip labral reconstruction and augmentation. Ready-to-use sterile device that saves 24-45 minutes by eliminating pre-operative manual allograft preparation. Available in three trimmable lengths and two diameter options.

4AlloConnex Tendons, Ligaments & Fascia
CategoryTendons, Ligaments & Fascia
Description

Portfolio of tendons, ligaments, and fascia allografts processed with AlloTrue tissue cleansing process and terminal sterilization for sports medicine procedures.

5AlloFlex Flexible Bone Matrix
CategoryBone Matrix
Description

Flexible bone matrix product for orthopedic applications.

6AlloFuse Select Cellular Bone Matrix
CategoryCellular Bone
Description

Cellular allograft in a moldable matrix indicated for general bone grafting in orthopedic and spinal fusion procedures. Delivers osteoconductive, osteoinductive, and osteogenic properties. Available in 1cc, 5cc, and 10cc vials.

7AlloFuse Cervical Spacers
CategoryBone / Spine
Description

Cortical and cortical/cancellous bone spacers for spinal fusion procedures.

8AlloFuse Fibers & Fiber Boats
CategoryDemineralized Bone Matrix
Description

Demineralized bone matrix products in fiber and fiber boat formats.

9AlloFuse Paste, Putty & Gel
CategoryDemineralized Bone Matrix
Description

Demineralized bone matrix in paste, putty, and gel formulations for bone grafting applications.

10AlloMend Acellular Dermal Matrix
CategoryAcellular Dermal Matrix
Description

Flexible acellular dermal matrix with ultimate tensile strength exceeding leading competitors. Features terminal sterilization with e-beam technology to SAL of 10-6. Processed with proprietary DermaTrue Decellularization Process. Available in multiple thicknesses and sizes.

11AlloMend Duo Acellular Dermal Matrix
CategoryAcellular Dermal Matrix
Description

Acellular dermal matrix variant for demanding soft tissue repair and reconstruction applications.

12AlloSkin Split-Thickness Dermis
CategorySkin / Dermis
Description

Split-thickness dermis allograft for burn and wound care applications.

13AlloSkin AC Acellular Dermal Substrate
CategoryAcellular Dermal Substrate
Description

Acellular dermal substrate for regenerative medicine applications.

14AlloWrap Amniotic Membrane
CategoryAmnion
Description

Amniotic membrane allograft for wound care and surgical applications.

15Cortical/Cancellous Bone
CategoryBone
Description

Bone allograft products including cortical and cancellous bone for orthopedic and spinal applications.

16Costal Cartilage
CategoryCartilage
Description

Cartilage allograft derived from costal (rib) cartilage for reconstructive procedures.

17ProChondrix CR Cryopreserved Osteochondral Allograft
CategoryCartilage
Description

Cryopreserved osteochondral allograft processed with ViaTrue Cryopreservation Process for knee cartilage repair. Maintains high chondrocyte viability for up to two years.

18PureSkin Dermal Tissue
CategoryDermis
Description

Dermis allograft for plastic and reconstructive surgery applications.

19Reconstructive Bone
CategoryBone
Description

Bone allograft for reconstructive surgical procedures.

20Structural Bone
CategoryBone
Description

Structural bone allograft for load-bearing orthopedic applications.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership12 partners
1Donor Alliance
Strategic tierCoreTypeOthers
Description

Donor Alliance is one of three founding OPO members that established AlloSource in 1994. Based in Denver, CO, Donor Alliance works collaboratively with AlloSource to maximize tissue donation and its benefits, recovering tissue from donors for processing into AlloSource allograft products.

allosource.org
Strategic tierCoreTypeOthers
Description

Gift of Hope is a founding OPO member of AlloSource, based in Chicago, IL. The organization recovers tissue from donors and works collaboratively with AlloSource to maximize the impact of tissue donation for patients in need.

3Iowa Donor Network
Strategic tierCoreTypeOthers
Description

Iowa Donor Network is a founding OPO member of AlloSource, based in North Liberty, IA. The organization serves as a true partner working collaboratively with AlloSource to maximize tissue donation and benefits.

allosource.org
Strategic tierCoreTypeOthers
Description

Mid-America Transplant is a founding OPO member of AlloSource, based in St. Louis, MO. The organization collaborates with AlloSource to maximize tissue donation outcomes and benefits to patients.

5ConnectLife
Strategic tierCoreTypeOthers
Description

ConnectLife is a founding OPO member of AlloSource, based in Buffalo, NY. As a true partner, ConnectLife works collaboratively with AlloSource to maximize tissue donation and its benefits.

allosource.org
Strategic tierMinorTypeOthers
Description

Network For Hope is a recovery partner OPO based in Cincinnati, OH, working with AlloSource to support tissue donation recovery operations.

Strategic tierMinorTypeOthers
Description

LifeLink is a recovery partner OPO based in Tampa, FL, supporting AlloSource's tissue donation recovery network.

Strategic tierMinorTypeOthers
Description

Lifesharing is a recovery partner OPO based in San Diego, CA, supporting AlloSource's tissue donation recovery network.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

AlloSource collaborated with Colorado State University's Orthopaedic Research Center (directed by Dr. Laurie Goodrich) on research comparing cryopreserved vs. fresh osteochondral allografts. The study found no significant difference between storage conditions, indicating cryopreservation is a promising alternative to fresh grafting practices.

Strategic tierMinorTypeOthers
Description

AlloSource serves as co-applicant for grant awards through the National Institute of Health as part of its sponsored investigator award program and grant co-application initiatives.

11Department of Defense (DoD)
Strategic tierMinorTypeOthers
Description

AlloSource serves as co-applicant for grant awards through the Department of Defense, supporting research into human tissue applications for military medicine and trauma care.

allosource.org
Strategic tierMinorTypeOthers
Description

AlloSource participates as co-applicant for grant awards through the National Science Foundation and serves as contractor for small business awards as part of its innovation and research support programs.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

MiMedx is a for-profit regenerative medicine company specializing in amniotic membrane and placental tissue allografts (EpiFix, AmnioFix). It directly competes with AlloSource's AlloWrap and other soft tissue allograft lines in wound care and surgical applications.

TypeBroad incumbent
Description

Smith+Nephew is a global medical device company with sports medicine and advanced wound management divisions that overlap with AlloSource's orthopedic allografts and skin substitute lines. A broad incumbent rather than a tissue-focused specialist.

TypeDirect peer
Description

LifeNet Health is a nonprofit allograft provider offering dermal, bone, tendon, and cardiovascular tissue products with proprietary processing technologies. Directly comparable to AlloSource in serving hospitals and surgeons with processed human tissue allografts.

TypeDirect peer
Description

MTF Biologics is one of the largest nonprofit tissue banks in the US, processing donated human tissue into allografts for orthopedics, sports medicine, and wound care. It is the closest direct peer to AlloSource in scale, nonprofit structure, and product portfolio breadth.

TypeDirect peer
Description

Organogenesis manufactures regenerative medicine products including skin substitutes (Apligraf), wound care devices, and surgical biologics. It overlaps with AlloSource's AlloSkin/PureSkin lines in burn/wound care and competes in adjacent regenerative medicine categories.

TypeBroad incumbent
Description

Stryker is a major orthopedic medical device company whose sports medicine and biologics offerings overlap with AlloSource's orthopedic allograft lines. Competes across multiple specialties as part of a broad medtech portfolio rather than as a tissue specialist.

TypeBroad incumbent
Description

Arthrex is a privately-held leader in sports medicine and orthopedics offering a broad portfolio that includes biologic/sports medicine allografts and procedural solutions. Overlaps with AlloSource in sports medicine allografts as part of a much wider orthopedic device portfolio.

TypeBroad incumbent
Description

Medtronic is a diversified medical device leader whose spine and biologics divisions overlap with AlloSource's AlloFuse bone matrix and spinal fusion allograft products. Serves the same hospital call points as part of a much broader portfolio.

TypeBroad incumbent
Description

Conmed is a medical device company with sports medicine and general surgery offerings that overlap with AlloSource's orthopedic and soft tissue allograft lines. A broad incumbent across multiple surgical specialties.

TypeBroad incumbent
Description

Integra LifeSciences is a public medical device company with a significant regenerative tissue technologies segment (Integra Dermal Regeneration Template, etc.). It competes with AlloSource in dermal matrices and regenerative wound care as part of a diversified neurosurgery and orthopedics portfolio.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance23 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

AlloSource

Human Tissue Allograftsallosource.org

AlloSource is a nonprofit human tissue processor that transforms donated tissue into 200,000+ allograft products annually across 11 tissue types and 8 surgical specialties, serving hospitals, surgery centers, and orthopedic practices in the US and internationally through direct sales and distributors.

What AlloSource does

AlloSource is a nonprofit human tissue processor founded in 1994 in Centennial, Colorado, by three Organ Procurement Organizations (Donor Alliance, Gift of Hope Organ & Tissue Donor Network, and Iowa Donor Network). It transforms donated human tissue into allograft products across 11 tissue types — dermis, cartilage, tendon, fascia, bone, and amnion — serving 8 surgical specialties including orthopedics, sports medicine, spine, plastics and reconstruction, urogynecology, burn and wound care, and foot and ankle. The company is governed by a board composed of OPO executives, with no external PE or VC ownership, and operates from a 160,000-square-foot headquarters containing 37 clean rooms and multiple laboratory spaces.

AlloSource's product platform rests on three proprietary processing technologies: ViaTrue Cryopreservation (controlled-rate freezing of fresh cartilage within 72 hours of donor death, maintaining high chondrocyte viability for up to two years), AlloTrue Tissue Cleansing (deep-tissue cleansing that removes blood and lipids while preserving biomechanical properties), and DermaTrue Decellularization (which removes cellular debris to render tissue acellular while preserving native collagen structure). Products such as AlloMend are terminally sterilized with e-beam technology to a Sterility Assurance Level of 10^-6. The company holds 100+ patents across these processes and has recorded zero confirmed disease transmission incidents over 20+ years of processing, with an estimated transmission risk below 1 in 1.6 million. Differentiated pre-sutured ready-to-use devices (AceConnex for hip labral reconstruction, ReConnex for ACL reconstruction) eliminate 24-45 minutes of OR preparation time.

AlloSource generates revenue by processing and distributing allograft products to hospitals, surgery centers, and orthopedic practices. Distribution is handled through an independent distributor network and a field-based direct sales team, supported by nine regional distribution centers across the United States and contracts with all national GPOs and hundreds of integrated delivery networks. International distribution extends to the Asia Pacific Rim, EU, Latin America, and South America under Health Canada, EU tissue directive, Korean, and Taiwan FDA compliance. Pricing is not publicly disclosed; hospital purchasing terms include annual CPI-linked price adjustment caps. The company employs more than 500 people and distributes more than 200,000 allografts annually (up from approximately 14,000 in 1994), with key leadership including President and CEO Dean Elliott, CFO Yan Deng, and Chief Commercial Officer Kevin Whitten.

AlloSource firmographics

Firmographics
Name
AlloSource
Legal name
AlloSource
Website
https://allosource.org
Company type
Private
Founded year
1994
Operating status
Operating
Headcount range
251–500 employees
Short description
AlloSource is a nonprofit human tissue processor that transforms donated tissue into 200,000+ allograft products annually across 11 tissue types and 8 surgical specialties, serving hospitals, surgery centers, and orthopedic practices in the US and internationally through direct sales and distributors.
Ownership category
akta.pro rank

AlloSource industry classification

Industry
Product category
Human Tissue Allografts
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Surgical Appliance and Supplies Manufacturing (339113)
SIC
Biological Products, (No Disgnostic Substances) (2836), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
akta.pro industry
PRIMARYHLAAAGAH
Cartilage, Bone & Musculoskeletal Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

Keywords

  • Human tissue allografts
  • Acellular dermal matrix
  • Orthopedic tissue products
  • Bone grafting materials
  • Tissue banking services

Where AlloSource is headquartered

Location

Headquarters

HQ city
Centennial
HQ country
United States
HQ region
North America

Offices8 records

Markets served

AlloSource business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Personnel, Technology or R&D, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

  1. Human Tissue Allograft Products: AlloSource generates revenue by processing and distributing human tissue allografts (dermis, cartilage, tendon, fascia, bone, and amnion) to hospitals, surgery centers, and orthopedic surgeons for use in various surgical procedures including knee replacement, bone grafts, spinal fusions, eye surgery, and skin grafts.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

AlloSource product offering

Product offering

Core offering

AlloSource processes donated human tissue into allograft products for surgical use, offering a comprehensive portfolio of dermis, cartilage, tendon, fascia, bone, and amnion allografts serving orthopedics, sports medicine, spine, plastics/reconstruction, urogynecology, burn, and wound care specialties. Products are developed using proprietary processing technologies including ViaTrue cryopreservation, AlloTrue cleansing, and DermaTrue decellularization, and are distributed to hospitals, surgery centers, and orthopedic practices.

Product overview

AlloSource is one of the largest human tissue providers, offering a comprehensive portfolio of innovative allograft products derived from donated human tissue. The portfolio includes multiple product lines organized by tissue type: Acellular Dermal Matrix products (AlloMend line with variants including Duo, Ultra Thick, Extra-Large, and Mesh Shaped), Skin products (AlloSkin, PureSkin), Cartilage products (ProChondrix CR, Costal Cartilage), Bone products (AlloFuse line including Select, Cervical Spacers, Fibers, Paste/Putty/Gel; Cortical/Cancellous Bone, Structural Bone, Reconstructive Bone), Tendon/Ligament products (AlloConnex portfolio including ReConnex Pre-Sutured Tendon, AceConnex Pre-Sutured Fascia), Fascia products (UroConnex), and Amnion products (AlloWrap). Products serve multiple surgical specialties including burn care, foot & ankle, orthopedics, plastics/reconstruction, spine, sports medicine, urogynecology, and wound care.

Differentiator

Problem solved

Functional benefit

Brands

  • AceConnex: Pre-Sutured Fascia product line for hip labral reconstruction
  • AlloConnex
  • AlloFlex
  • AlloFuse
  • AlloMend
  • AlloSkin
  • AlloWrap
  • ProChondrix CR
  • PureSkin
  • ReConnex
  • UroConnex

Products and services

  • ReConnex Pre-Sutured Tendon FDA 510(k) cleared ready-to-use sterile pre-sutured tendon allograft designed for all-inside Anterior Cruciate Ligament (ACL) reconstruction procedures. Features validated suture and knot pull-out strength with diameters 8.0-10.5mm and lengths 66mm +/-4mm.
  • UroConnex Fascia allograft offered in freeze-dried and frozen varieties with a wide range of sizes for structural support in surgical procedures. Provides an alternative to autologous fascia with terminal sterilization (irradiated to SAL of 10-6).
  • AceConnex Pre-Sutured Fascia Only 510(k) cleared pre-sutured fascia allograft for hip labral reconstruction and augmentation. Ready-to-use sterile device that saves 24-45 minutes by eliminating pre-operative manual allograft preparation. Available in three trimmable lengths and two diameter options.
  • AlloConnex Tendons, Ligaments & Fascia Portfolio of tendons, ligaments, and fascia allografts processed with AlloTrue tissue cleansing process and terminal sterilization for sports medicine procedures.
  • AlloFlex Flexible Bone Matrix Flexible bone matrix product for orthopedic applications.
  • AlloFuse Select Cellular Bone Matrix Cellular allograft in a moldable matrix indicated for general bone grafting in orthopedic and spinal fusion procedures. Delivers osteoconductive, osteoinductive, and osteogenic properties. Available in 1cc, 5cc, and 10cc vials.
  • AlloFuse Cervical Spacers Cortical and cortical/cancellous bone spacers for spinal fusion procedures.
  • AlloFuse Fibers & Fiber Boats Demineralized bone matrix products in fiber and fiber boat formats.
  • AlloFuse Paste, Putty & Gel Demineralized bone matrix in paste, putty, and gel formulations for bone grafting applications.
  • AlloMend Acellular Dermal Matrix Flexible acellular dermal matrix with ultimate tensile strength exceeding leading competitors. Features terminal sterilization with e-beam technology to SAL of 10-6. Processed with proprietary DermaTrue Decellularization Process. Available in multiple thicknesses and sizes.
  • AlloMend Duo Acellular Dermal Matrix Acellular dermal matrix variant for demanding soft tissue repair and reconstruction applications.
  • AlloSkin Split-Thickness Dermis Split-thickness dermis allograft for burn and wound care applications.
  • AlloSkin AC Acellular Dermal Substrate Acellular dermal substrate for regenerative medicine applications.
  • AlloWrap Amniotic Membrane Amniotic membrane allograft for wound care and surgical applications.
  • Cortical/Cancellous Bone Bone allograft products including cortical and cancellous bone for orthopedic and spinal applications.
  • Costal Cartilage Cartilage allograft derived from costal (rib) cartilage for reconstructive procedures.
  • ProChondrix CR Cryopreserved Osteochondral Allograft Cryopreserved osteochondral allograft processed with ViaTrue Cryopreservation Process for knee cartilage repair. Maintains high chondrocyte viability for up to two years.
  • PureSkin Dermal Tissue Dermis allograft for plastic and reconstructive surgery applications.
  • Reconstructive Bone Bone allograft for reconstructive surgical procedures.
  • Structural Bone Structural bone allograft for load-bearing orthopedic applications.

Quantifiable outcome

  • Zero confirmed disease transmission incidents in over 20 years of tissue processing
  • +5 more outcomes

Companies that use AlloSource

Customer profile

Named customers3 records

Segments6 records

Ideal customer profiles2 records

AlloSource technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

AlloSource partnerships and signals

Strategic signal

Partnerships

Twelve partnerships are on record, tiered core and minor.

  • Donor AlliancecoreOthersDonor Alliance is one of three founding OPO members that established AlloSource in 1994. Based in Denver, CO, Donor Alliance works collaboratively with AlloSource to maximize tissue donation and its benefits, recovering tissue from donors for processing into AlloSource allograft products.
  • Gift of Hope Organ & Tissue Donor NetworkcoreOthersGift of Hope is a founding OPO member of AlloSource, based in Chicago, IL. The organization recovers tissue from donors and works collaboratively with AlloSource to maximize the impact of tissue donation for patients in need.
  • Iowa Donor NetworkcoreOthersIowa Donor Network is a founding OPO member of AlloSource, based in North Liberty, IA. The organization serves as a true partner working collaboratively with AlloSource to maximize tissue donation and benefits.
  • Mid-America TransplantcoreOthersMid-America Transplant is a founding OPO member of AlloSource, based in St. Louis, MO. The organization collaborates with AlloSource to maximize tissue donation outcomes and benefits to patients.
  • ConnectLifecoreOthersConnectLife is a founding OPO member of AlloSource, based in Buffalo, NY. As a true partner, ConnectLife works collaboratively with AlloSource to maximize tissue donation and its benefits.
  • Network For HopeminorOthersNetwork For Hope is a recovery partner OPO based in Cincinnati, OH, working with AlloSource to support tissue donation recovery operations.
  • LifeLinkminorOthersLifeLink is a recovery partner OPO based in Tampa, FL, supporting AlloSource's tissue donation recovery network.
  • Lifesharing Community Organ & Tissue DonationminorOthersLifesharing is a recovery partner OPO based in San Diego, CA, supporting AlloSource's tissue donation recovery network.
  • Colorado State University - Orthopaedic Research CenterminorStrategic or Co-development PartnerAlloSource collaborated with Colorado State University's Orthopaedic Research Center (directed by Dr. Laurie Goodrich) on research comparing cryopreserved vs. fresh osteochondral allografts. The study found no significant difference between storage conditions, indicating cryopreservation is a promising alternative to fresh grafting practices.
  • National Institute of Health (NIH)minorOthersAlloSource serves as co-applicant for grant awards through the National Institute of Health as part of its sponsored investigator award program and grant co-application initiatives.
  • Department of Defense (DoD)minorOthersAlloSource serves as co-applicant for grant awards through the Department of Defense, supporting research into human tissue applications for military medicine and trauma care.
  • National Science Foundation (NSF)minorOthersAlloSource participates as co-applicant for grant awards through the National Science Foundation and serves as contractor for small business awards as part of its innovation and research support programs.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

AlloSource competitors and assessment

Company assessment

Direct peers

  • MiMedx: MiMedx is a for-profit regenerative medicine company specializing in amniotic membrane and placental tissue allografts (EpiFix, AmnioFix). It directly competes with AlloSource's AlloWrap and other soft tissue allograft lines in wound care and surgical applications.
  • LifeNet Health: LifeNet Health is a nonprofit allograft provider offering dermal, bone, tendon, and cardiovascular tissue products with proprietary processing technologies. Directly comparable to AlloSource in serving hospitals and surgeons with processed human tissue allografts.
  • MTF Biologics: MTF Biologics is one of the largest nonprofit tissue banks in the US, processing donated human tissue into allografts for orthopedics, sports medicine, and wound care. It is the closest direct peer to AlloSource in scale, nonprofit structure, and product portfolio breadth.
  • Organogenesis: Organogenesis manufactures regenerative medicine products including skin substitutes (Apligraf), wound care devices, and surgical biologics. It overlaps with AlloSource's AlloSkin/PureSkin lines in burn/wound care and competes in adjacent regenerative medicine categories.

Broad incumbents

  • Smith+Nephew: Smith+Nephew is a global medical device company with sports medicine and advanced wound management divisions that overlap with AlloSource's orthopedic allografts and skin substitute lines. A broad incumbent rather than a tissue-focused specialist.
  • Stryker: Stryker is a major orthopedic medical device company whose sports medicine and biologics offerings overlap with AlloSource's orthopedic allograft lines. Competes across multiple specialties as part of a broad medtech portfolio rather than as a tissue specialist.
  • Arthrex: Arthrex is a privately-held leader in sports medicine and orthopedics offering a broad portfolio that includes biologic/sports medicine allografts and procedural solutions. Overlaps with AlloSource in sports medicine allografts as part of a much wider orthopedic device portfolio.
  • Medtronic: Medtronic is a diversified medical device leader whose spine and biologics divisions overlap with AlloSource's AlloFuse bone matrix and spinal fusion allograft products. Serves the same hospital call points as part of a much broader portfolio.
  • Conmed: Conmed is a medical device company with sports medicine and general surgery offerings that overlap with AlloSource's orthopedic and soft tissue allograft lines. A broad incumbent across multiple surgical specialties.
  • Integra LifeSciences: Integra LifeSciences is a public medical device company with a significant regenerative tissue technologies segment (Integra Dermal Regeneration Template, etc.). It competes with AlloSource in dermal matrices and regenerative wound care as part of a diversified neurosurgery and orthopedics portfolio.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

AlloSource social profiles

Digital presence

AlloSource compliance and trust

Trust signal

Compliance23 records

AlloSource financial estimates

Financial estimate

Revenue estimate

Valuation estimate

AlloSource leadership team

Management profile

Number of profiles

Profiles13 records

AlloSource funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

AlloSource M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AlloSource

What does AlloSource do?

AlloSource processes donated human tissue into allograft products for surgical use, offering a comprehensive portfolio of dermis, cartilage, tendon, fascia, bone, and amnion allografts serving orthopedics, sports medicine, spine, plastics/reconstruction, urogynecology, burn, and wound care specialties. Products are developed using proprietary processing technologies including ViaTrue cryopreservation, AlloTrue cleansing, and DermaTrue decellularization, and are distributed to hospitals, surgery centers, and orthopedic practices.

Is AlloSource a public or private company?

AlloSource is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was AlloSource founded?

AlloSource was founded in 1994. It employs 251 to 500 people.

Where is AlloSource based?

AlloSource is headquartered in Centennial, United States, in the North America region.

How does AlloSource make money?

One revenue line is on record: human Tissue Allograft Products.

Who are AlloSource's main competitors?

Direct peers on record are MiMedx, LifeNet Health, MTF Biologics and Organogenesis. Broad incumbents are Smith+Nephew, Stryker, Arthrex, Medtronic, Conmed and Integra LifeSciences.

Does AlloSource have an API?

No public API is recorded for AlloSource.

What industry is AlloSource in?

AlloSource's product category is Human Tissue Allografts. Its primary akta.pro industry code is HLAAAGAH, Cartilage, Bone & Musculoskeletal Regeneration. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireALLOSOURCE® LAUNCHES UROCONNEX™ FASCIA AS PART OF ITS PORTFOLIO OF ALLOGRAFTS FOR USE IN WOMEN'S HEALTH PROCEDURESAlloSource announced the launch of UroConnex Fascia, a human fascia allograft for women's health procedures, available in freeze-dried and frozen formats. The product offers structural support and reduces patient risk by providing an alternative to autologous fascia. It is terminally sterilized to a SAL of 10-6.PR NewswireDR. VICTOR STAMS, DR. SIGRID BLOME-EBERWEIN, AND DR. ROBERT MEISLIN RECOGNIZED BY ALLOSOURCE WITH THE DR. STEVEN GITELIS INSPIRATION AWARD FOR HONORING THE GIFT OF DONATIONAlloSource awarded Dr. Victor Stams, Dr. Sigrid Blome-Eberwein, and Dr. Robert Meislin the Dr. Steven Gitelis Inspiration Award for using donated human tissue to improve patient care. Each winner received a monetary contribution to a charity of their choice, with Stams selecting the Boys and Girls Club, Blome-Eberwein the REACH Burn Foundation, and Meislin the Heschel School.BioSpaceALLOSOURCE® INTRODUCES FDA 510(K) CLEARED RECONNEX™ PRE-SUTURED TENDON FOR ALL-INSIDE ANTERIOR CRUCIATE LIGAMENT PROCEDURESAlloSource announced the launch of ReConnex Pre-Sutured Tendon, an FDA 510(k) cleared pre-sutured tendon for all-inside ACL reconstruction. The product comes in diameters of 8-10.5 mm and is designed to simplify procedures by eliminating manual suturing. It is part of the AlloConnex portfolio and uses the AlloTrue cleansing process.PR NewswireALLOSOURCE® INTRODUCES FDA 510(K) CLEARED RECONNEX™ PRE-SUTURED TENDON FOR ALL-INSIDE ANTERIOR CRUCIATE LIGAMENT PROCEDURESAlloSource launched ReConnex Pre-Sutured Tendon, an FDA 510(k) cleared tendon for all-inside ACL reconstruction. The product comes in diameters of 8-10.5 mm with white loop sutures for suspensory fixation. It is cleansed with AlloTrue and irradiated to ensure sterility.openPR.comACL Reconstruction Procedures Market Overview, Key Trends, and Major Player AnalysisThe global ACL reconstruction procedures market is projected to reach $11.2 billion by 2030, growing at a compound annual growth rate of 7.2%, driven by advances in graft fixation devices, minimally invasive surgical techniques, and increasing sports-related injuries. In July 2024, Stryker Corporation acquired Artelon Inc., a biotechnology company specializing in soft tissue repair and regeneration solutions, to strengthen Stryker's portfolio in soft tissue fixation for foot, ankle, and sports medicine procedures. Additional market activity includes AlloSource's May 2023 launch of the AlloMend Duo Acellular Dermal Matrix for soft tissue reconstruction.PR NewswireALLOSOURCE® ANNOUNCES RESEARCH FEATURING ITS PROPRIETARY VIATRUE® CRYOPRESERVATION PROCESS IS BEING PRESENTED AT THE 18TH INTERNATIONAL CARTILAGE REGENERATION & JOINT PRESERVATION SOCIETY WORLD CONGREAlloSource announced that research featuring its proprietary ViaTrue Cryopreservation Process is being presented at the 18th ICRS World Congress, with studies demonstrating positive clinical outcomes for its cartilage allograft products. The first study on ProChondrix CR showed significant improvements in patient-reported outcome scores up to 60 months for knee cartilage repair, while a second study conducted with Colorado State University found no significant difference between cryopreserved and fresh osteochondral allografts, suggesting extended shelf-life could improve accessibility.PR NewswireALLOSOURCE® ANNOUNCES 200TH IMPLANT OF ACECONNEX® PRE-SUTURED FASCIA DEVICE FOR HIP LABRAL RECONSTRUCTION AND AUGMENTATIONAlloSource announced the 200th implant of its AceConnex Pre-Sutured Fascia device, which is the only 510(k) cleared pre-sutured fascia allograft for hip labral reconstruction and augmentation. The pre-sutured device offers consistency and eliminates the time-consuming suturing process compared to allografts prepared in the operating room. This milestone reflects progress toward AlloSource's goal of providing innovative solutions for complex hip arthroscopy procedures.PR NewswireALLOSOURCE® RECOGNIZED WITH 2023 CIGNA HEALTHY WORKFORCE™ DESIGNATIONCigna Healthcare selected AlloSource as a recipient of the Gold level Healthy Workforce Designation for 2023, recognizing the organization's commitment to employee health and wellness through a comprehensive workplace well-being program. This represents a significant improvement from the Bronze designation AlloSource received in 2022. The award evaluates organizations on leadership and culture, program foundations and execution, and policies related to employee well-being.PR NewswireALLOSOURCE ANNOUNCES FIRST PATIENT IMPLANTATION IN UNITED KINGDOM CLINICAL EVALUATION OF PROCHONDRIX CR CRYOPRESERVED OSTEOCHONDRAL ALLOGRAFTAlloSource announced the first patient implantation of its ProChondrix CR Cryopreserved Osteochondral Allograft in a United Kingdom independent clinical evaluation, performed by Dr. Nick Smith at University Hospitals Coventry and Warwickshire NHS Trust. The procedure was completed successfully with the patient discharged the same day. The UK evaluation will assess clinical outcomes and complications of patients undergoing cartilage surgery using ProChondrix CR, a living cellular cartilage product with 94.97% chondrocyte viability after two years of cryopreserved storage and a two-year shelf life.PR NewswireALLOSOURCE ANNOUNCES POSTER FEATURING PROCHONDRIX CR OSTEOCHONDRAL ALLOGRAFT CLINICAL OUTCOMES AT THE 17TH INTERNATIONAL CARTILAGE REGENERATION & JOINT PRESERVATION SOCIETY (ICRS) WORLD CONGRESSAlloSource announced that research demonstrating positive prospective clinical outcomes for its ProChondrix CR cryopreserved osteochondral allograft in repairing focal articular cartilage defects in the knee will be presented at the ICRS World Congress in Barcelona, Spain from September 9-12, 2023. The clinical study showed significant improvements in all patient-reported outcome scores up to 36 months, suggesting the product is effective for active patients seeking to return to physically demanding lifestyles after injury. The company highlighted that this aligns with the ICRS theme of advancing science and treatments for cartilage and joint preservation.